Early Clinical Evidence Shows Surefire Technology Achieves 80%
Complete Tumor Response, Effective in Downstaging Patients to Transplant

Study presented at SIR Evaluated Efficacy of Surefire Technology
in Treatment of Primary Liver Cancer

 

April 4, 2016—Vancouver, Canada—Surefire Medical, Inc. today announced that early clinical data presented at the Society for Interventional Radiology (SIR) meeting in Vancouver, Canada showed the Surefire Infusion Technology effectively delivered therapy in the treatment of primary liver cancer (hepatocellular carcinoma or HCC) with an 80 percent complete tumor response and 93 percent objective tumor response.

The retrospective review of 11 patients with 21 separate lesions, which was conducted by Georgetown University via MedStar Georgetown University Hospital, studied the safety and efficacy of the Surefire Infusion System in chemoembolization procedures treating HCC in a 12-month period. Patient outcomes were assessed based upon the modified Response Evaluation Criteria in Solid Tumors (mRECIST) on follow-up imaging.

According to the published abstract, “The Surefire Infusion System [SIS] is a promising tool for delivery of DEB‐TACE in treatment of HCC and may lead to improved disease response when compared with delivery with standard end‐hole catheters.”

In a previously published clinical trial, the Surefire Infusion System increased tumor uptake by 68 percent and reduced treatment delivered to healthy tissue by 58 percent when compared to a standard microcatheter in treatment of multiple cancers of the liver.1

“This pilot study shows that site-specific delivery of therapy to cancers of the liver with the Surefire Infusion System can achieve very high complete response rates,” said James E. Chomas, President and CEO of Surefire Medical. “There is a growing body of evidence that achieving a complete response on a single procedure leads to significantly longer overall patient survival.2 Our technology allows Interventional Radiologists to achieve a new level of control and to standardize therapy delivery to the tumor.”

Researchers plan to conduct a prospective trial to validate these initial findings.

1 A. Pasciak, et al. “The Impact of an Antireflux Catheter on Target Volume Particle Distribution in Liver-Directed Embolotherapy: A Pilot Study”, J Vasc Interv Radiol 2015; 26:660–669.

2Kim et al. “The Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma,” J. of Hepatology 2015 vol. 62, 1304–1310.

 

About Surefire Medical

Surefire Medical is inventing the future for cancer care with advanced treatment technology. We are pioneers, developing liver cancer infusion systems that overcome the limitations of traditional tools and delivery methods. Clinical discoveries paired with new, precise technology arm physicians to target tumors with superior accuracy, control and protection. Our Colorado-based team of physicians, engineers and researchers are united in a mission to progress cancer care and offer new hope to patients. Learn more: www.surefiremedical.com.

Achievement

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.